Skip to main content
Log in

68Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer

  • Case Report
  • Published:
Abdominal Imaging Aims and scope Submit manuscript

Abstract

Current imaging procedures for prostate cancer including positron emission tomography (PET) exhibit considerable limitations and are not always able to meet the diagnostic needs. Recently, a 68Gallium-labeled ligand of the prostate-specific membrane antigen (68Ga-PSMA) has been introduced in PET-imaging of prostate cancer with first promising results. Due to relatively exclusive expression of PSMA in prostatic tissue as well as increased expression in prostate cancer, 68 Ga-PSMA was reported to exhibit a favorable lesion to background ratio. Together with the novel development of combined PET/MRI, the combination of excellent morphological detail, multiparametric functional information, and molecular PET data might lead to a significant improvement in detection of prostate cancer. We present an exemplarily case of primary staging using multiparametric 68Ga-PSMA PET/MR by combining molecular and structural information.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Linhart HG (2014) Comparison of PET imaging with a 68 Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 41:11–20

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, et al. (2014) Comparison of PET/CT and PET/MRI hybrid systems using a 68 Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur. J. Nucl. Med. Mol. Imaging. 41:887–897

    Article  CAS  PubMed  Google Scholar 

  3. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM (2012) [68 Ga] Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18 F-FECH. Eur. J. Nucl. Med. Mol. Imaging 39(6):1085–1086

    Article  CAS  PubMed  Google Scholar 

  4. Metz S, Ganter C, Lorenzen S, et al. (2010) Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nuc Med 51:1691–1698

    Article  Google Scholar 

  5. Chen Y-J, Chu W-C, Pu Y-S, et al. (2012) Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer. J. Magn. Reson. Imaging JMRI. 36:912–919

    Article  PubMed  Google Scholar 

  6. Oto A, Yang C, Kayhan A, et al. (2011) Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am. J. Roentgenol 197:1382–1390

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Matthias Eiber.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eiber, M., Nekolla, S.G., Maurer, T. et al. 68Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging 40, 1769–1771 (2015). https://doi.org/10.1007/s00261-014-0301-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-014-0301-z

Keywords

Navigation